Lundbeck Canada History

Improving the quality of life for Canadians with brain diseases since 1995


During the 1990s, Lundbeck opened subsidiary operations in 20 countries including Canada. Based on the world-wide introduction of Citalopram an antidepressant known as a selective serotonin reuptake inhibitor (SSRI), Lundbeck established Canadian operations to ensure the availability of Celexa® (citalopram) as it is known in Canada.

A dedicated group of employees began forging relationships with Canadian physicians building awareness of the company and two important products for the treatment of schizophrenia: Clopixol® and Fluanxol®, both used today. Celexa® (citalopram) received regulatory approval from Health Canada in 1999, confirming Lundbeck’s commitment in the Canadian market. Today 225 Canadians work at Lundbeck Canada.

Celexa® (citalopram) became the most successful antidepressant in Canadian history. After the generic version of citalopram entered the market, Lundbeck Canada introduced two new products: Cipralex® (escitalopram), a second generation SSRI, and Ebixa® (memantine), the first drug in a new therapeutic class for moderate to severe Alzheimer's disease. The company continues to lead Canadian-based clinical research activity focused on brain diseases as Canadian researchers conduct trials with Lundbeck products and pursue innovative treatments for Canadians.

Lundbeck Canada also made available Treanda®  for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma and Trisenox for the treatment of acute  promyelocytic leukemia, enabling Lundbeck Canada to create new partnerships with healthcare professionals in the field of oncology.

You are now leaving , Lundbeck Canada’s Web site. Links to site outside of Lundbeck Canada are provided as resources to visitors and may not represent Canada regulation or prescribing information. Lundbeck Canada accepts no responsibility in the content of linked sites.